Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR -0.53%40 Forward Dividend Yield % is 0.00% as of Aug. 31, 2026. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 505 Drug Manufacturers companies, J.Molner AS ranks worse than 198019.6% on this metric.
As of today (2026-08-31), the Forward Annual Dividend Yield of J.Molner AS is 0.00%.
As of today (2026-08-31), the Trailing Annual Dividend Yield of J.Molner AS is 0.00%.
OTSE:MOLNR's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.04 * Ranked among companies with meaningful Forward Dividend Yield % only.
J.Molner AS (OTSE:MOLNR) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
J.Molner AS Forward Dividend Yield % Related Terms
OTSE:MOLNR vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
J.Molner AS (OTSE:MOLNR) has a Forward Dividend Yield % of 0.00% as of Aug. 31, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on J.Molner AS and its competitors. According to the industry distribution chart, J.Molner AS ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is J.Molner AS's Forward Dividend Yield % too high?
J.Molner AS's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, J.Molner AS ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #999999 out of 505 companies for Forward Dividend Yield %. This places J.Molner AS in the lower half of its industry. The industry median Forward Dividend Yield % is 2.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.04, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Forward Dividend Yield % is 0.00% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Forward Dividend Yield %: 0.00%
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
